Physician profile
Henna Sheikh
NPI 1477887560
$683.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $293.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.39 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $126.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $116.99 | 2019 | |
| Novo Nordisk INC | $103.31 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $76.67 | 2019-2020 | |
| Lilly USA, LLC | $26.91 | 2020 | |
| Amarin Pharma, INC. | $21.06 | 2020 | |
| Astellas Pharma US INC | $16.68 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.05 | 2020 | |
| Amgen INC. | $15.15 | 2020 | |
| Glaxosmithkline, LLC. | $12.36 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henna Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.